Last reviewed · How we verify
SB-656933-AAA
At a glance
| Generic name | SB-656933-AAA |
|---|---|
| Also known as | SB-656933 |
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Pharmacodynamics of SB-656933 in Patients With Ulcerative Colitis (PHASE2)
- Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone (PHASE1)
- A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SB-656933-AAA CI brief — competitive landscape report
- SB-656933-AAA updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI